Profile
Xiao Hui Gu worked as an Executive Director of Medicinal Chemistry at Pharmaron Beijing Co., Ltd.
and as a Principal at Exelixis, Inc. Prior to that, from 2001 to 2008, Gu worked at X-Ceptor Therapeutics, Inc. as a Principal.
Gu received an undergraduate degree from Hunan Normal University and graduate and doctorate degrees from Shanghai Institute of Organic Chemistry.
Former positions of Xiao Hui Gu
| Companies | Position | End |
|---|---|---|
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | 01/01/2008 |
| EXELIXIS, INC. | Corporate Officer/Principal | - |
| PHARMARON BEIJING CO., LTD. | Corporate Officer/Principal | - |
Training of Xiao Hui Gu
| Hunan Normal University | Undergraduate Degree |
| Shanghai Institute of Organic Chemistry | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| PHARMARON BEIJING CO., LTD. | Commercial Services |
| EXELIXIS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Stock Market
- Insiders
- Xiao Hui Gu
